6533b82dfe1ef96bd129144f

RESEARCH PRODUCT

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

Bruno MartinoDaniele CattaneoMarco CerranoElisabetta AbruzzeseGiuseppe SaglioFausto CastagnettiMarco SantoroSabina RussoSara GalimbertiLuciano LevatoMonica CrugnolaValentina GiaiMassimo BrecciaChiara ElenaGiovanna Rege CambrinIrene DogliottiAlessandra IurloPaola BerchiallaFrancesca LunghiMichele CedroneNicola SgherzaMatteo DraganiLuigia LucianoAntonella GozziniFederica SoràMonica BocchiaGianantonio RostiIsabella CapodannoGiovanni CaocciCarmen FavaDario FerreroCarlo Gambacorti-passerini

subject

medicine.medical_specialtymedicine.drug_classlcsh:MedicineTyrosine-kinase inhibitorArticle03 medical and health sciences0302 clinical medicinechronic myeloid leukemiahemic and lymphatic diseasesInternal medicineRetrospective analysisMedicineIn patientchronic myeloid leukemia; treatment-free remission; molecular monitoringtreatment-free remissionbusiness.industrylcsh:RMyeloid leukemiaGeneral MedicineDiscontinuationmolecular monitoringchronic myeloid leukemia; molecular monitoring; treatment-free remission030220 oncology & carcinogenesisMajor Molecular ResponseCohortbusinessOff Treatment030215 immunology

description

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported&mdash

yearjournalcountryeditionlanguage
2020-11-17Journal of clinical medicine
10.3390/jcm9113692https://pubmed.ncbi.nlm.nih.gov/33213044